- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01689779
High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status
August 29, 2017 updated by: Sadeq A. Quraishi, Massachusetts General Hospital
Effect of High-dose Cholecalciferol Supplementation on Perioperative Vitamin D Status in Colorectal Surgery Patients
A growing body of evidence suggests that robust postoperative immune function is associated with a lower risk of surgical site infections (SSIs).
At the same time, vitamin D is increasingly recognized as a key regulator of the innate and adaptive immune systems.
The investigators elected to conduct the current study in patients who will undergo colorectal surgery since these patients are historically at higher risk of developing SSIs and therefore would be ideal for future investigations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
While vitamin D insufficiency [25(OH)D <30 ng/mL] is common in the general population, hypovitaminosis D may affect 40-80% of patients in the perioperative setting.
Recent evidence also suggests that surgical stress may be associated with a 40% reduction in circulating 25(OH)D levels when compared to preoperative values.
Moreover, the derangement in perioperative 25(OH)D levels may be sustained for up to 3 months after surgery.
This finding has potential implications regarding modifiable risk factors for surgical site infections (SSIs), which account for nearly 40% of all nosocomial infections.
On aggregate, SSIs result in 3.7 million extra hospital days per annum and an added burden of $1.6 billion in annual healthcare costs.
A growing body of evidence suggests that robust postoperative immune function is associated with a lower risk of SSIs.
At the same time, vitamin D is increasingly recognized as a key regulator of the innate and adaptive immune systems.
Yet, optimization of perioperative vitamin D status remains grossly understudied.
Although our overarching aim is to study the impact of vitamin D status on SSIs, the focus of the current investigation is to determine whether the administration of a "bolus" oral dose of cholecalciferol (vitamin D3) in the preoperative setting alters vitamin D status in the perioperative setting (compared to a placebo).
The investigators elected to conduct the current study in patients who will undergo colorectal surgery since these patients are historically at higher risk of developing SSIs and therefore would be ideal for future investigations.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women;
- 18 years or older;
- Scheduled for elective (non-emergent) colorectal surgery;
- Cleared for anesthesia; and
- Expected to stay overnight following surgery
Exclusion Criteria:
- Scheduled for a purely laparoscopic procedure;
- Diagnosis of a terminal illness and/or in hospice care;
- Inability to sign informed consent;
- Inability to comply with study protocol;
- Intending to start vitamin D supplementation within 30 days of surgery;
- Intending to leave the Boston area during the follow-up period;
- History of renal stones or hypercalcemia;
- Medical conditions that can cause hypercalcemia (e.g. metastatic cancer, sarcoidosis, myeloma primary hyperparathyroidism)
- History of hypercalcemia
- History of severe anemia (Hematocrit <25%)
- Medications that affect vitamin D metabolism (e.g. anti-epileptics, tuberculosis medication); and
- Already enrolled or planning to enroll in a research study that would conflict with full participation in the current study or confound the observation or interpretation of the study findings
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cholecalciferol
A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
|
active drug
Other Names:
|
Placebo Comparator: Placebo
A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
|
comparator drug
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent (%) Change in 25(OH)D 5 Days Following Supplementation With 100,000 IU Cholecalciferol
Time Frame: Patients will be followed between the initial preoperative evaluation day and an average duration of 5 days
|
3-7 days before surgery, patients will receive 100,000 IU of cholecalciferol (vs.
placebo) during their pre-op assessment.
They will also have their baseline vitamin D status measured during this initial visit.
The main study outcome is to determine if 100,000 IU cholecalciferol can be given preoperatively to safely boost vitamin D status.
To assess vitamin D status, we will measure: 1) 25(OH)D and 2) LL37
|
Patients will be followed between the initial preoperative evaluation day and an average duration of 5 days
|
Percent (%) Change in LL-37 5 Days Following Supplementation With 100,000 IU Cholecalciferol
Time Frame: Patients will be followed between the initial preoperative evaluation day and an average duration of 5 days
|
3-7 days before surgery, patients will receive 100,000 IU of cholecalciferol (vs.
placebo) during their pre-op assessment.
They will also have their baseline vitamin D status measured during this initial visit.
The main study outcome is to determine if 100,000 IU cholecalciferol can be given preoperatively to safely boost vitamin D status.
To assess vitamin D status, we will measure: 1) 25(OH)D and 2) LL37
|
Patients will be followed between the initial preoperative evaluation day and an average duration of 5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent (%) Change in Pre-surgical 25(OH)D Within 24 Hours of Surgery
Time Frame: Patients will be followed between the day of surgery and 1 day after surgery
|
The goal is to determine whether pre-operative supplementation with 100,000 IU cholecalciferol (vs.
placebo) alters the natural course of short-term changes in vitamin D status following surgery.
To assess vitamin D status, we will measure: 1) 25(OH)D and 2) LL37.
|
Patients will be followed between the day of surgery and 1 day after surgery
|
Percent (%) Change in Pre-surgical LL-37 Within 24 Hours of Surgery
Time Frame: Patients will be followed between the day of surgery and 1 day after surgery
|
The goal is to determine whether pre-operative supplementation with 100,000 IU cholecalciferol (vs.
placebo) alters the natural course of short-term changes in vitamin D status following surgery.
To assess vitamin D status, we will measure: 1) 25(OH)D and 2) LL37.
|
Patients will be followed between the day of surgery and 1 day after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent (%) Change in Pre-surgical 25(OH)D 2 Weeks After Surgery
Time Frame: Patients will be followed between the day of surgery and an average duration of 14 days after surgery
|
The goal is to determine whether pre-operative supplementation with 100,000 IU cholecalciferol (vs.
placebo) alters the natural course of changes in vitamin D status within 10-18 days after surgery.
To assess vitamin D status, we will measure: 1) 25(OH)D and 2) LL-37.
|
Patients will be followed between the day of surgery and an average duration of 14 days after surgery
|
Percent (%) Change in Pre-surgical LL-37 2 Weeks After Surgery
Time Frame: Patients will be followed between the day of surgery and an average duration of 14 days after surgery
|
The goal is to determine whether pre-operative supplementation with 100,000 IU cholecalciferol (vs.
placebo) alters the natural course of changes in vitamin D status within 10-18 days after surgery.
To assess vitamin D status, we will measure: 1) 25(OH)D and 2) LL-37.
|
Patients will be followed between the day of surgery and an average duration of 14 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sadeq A Quraishi, MD, MHA, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
September 4, 2012
First Submitted That Met QC Criteria
September 17, 2012
First Posted (Estimate)
September 21, 2012
Study Record Updates
Last Update Posted (Actual)
September 28, 2017
Last Update Submitted That Met QC Criteria
August 29, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Nutrition Disorders
- Musculoskeletal Diseases
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Bone Diseases, Metabolic
- Calcium Metabolism Disorders
- Vitamin D Deficiency
- Rickets
- Avitaminosis
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- 2012P001852
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypovitaminosis D
-
Hospices Civils de LyonCompleted
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Silvana De Giorgi; Davide Bizzoca; Angela NotarnicolaRecruitingHypovitaminosis DItaly
-
Madigan Army Medical CenterCompletedHypovitaminosis DUnited States
-
University of TromsoCompleted
-
Jewish General HospitalMcGill UniversityCompleted
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Completed
-
Boston UniversityCompletedVitamin D Deficiency | Vitamin E Deficiency | Hypovitaminosis AUnited States
-
Harokopio UniversityUniversity College Cork; FrieslandCampinaCompletedHypovitaminosis D | Deficiency of MicronutrientsGreece
-
Chulalongkorn UniversityUnknownVitamin D2 Supplementation in Vitamin D InsufficiencyThailand
-
Charles Drew University of Medicine and ScienceNational Institute on Minority Health and Health Disparities (NIMHD); Morehouse...CompletedHypovitaminosis DUnited States
Clinical Trials on 100,000 IU cholecalciferol
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverCompletedInflammationUnited States
-
Green Cross CorporationUnknownHepatitis B InfectionKorea, Republic of
-
Peter DaleyDalhousie UniversityCompleted
-
Johns Hopkins UniversityNational Institute on Aging (NIA)TerminatedVitamin D Deficiency | FallsUnited States
-
Gary M Brittenham, MDCompletedVitamin D Deficiency | Asthma | Sickle Cell Disease | Acute Chest Syndrome | Respiratory InfectionsUnited States
-
King Faisal Specialist Hospital & Research CenterCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Medical University of South CarolinaTerminatedVitamin D Deficiency | Nutritional DeficiencyUnited States
-
University Hospital, AngersMylan LaboratoriesCompleted
-
University of California, San FranciscoCompleted